‚P¬’rKG‘¼@‚—îŽÒŠÌŠà‚ɑ΂·‚郉ƒWƒI”gĎܗÖ@@2003@“ú–{¬l•aŠw‰ï
‚Q¬’rKG‘¼@ŠÌŠàŽ¡—ÃŒã‚ÌŠÌ‹@”\„ˆÚ@2002@“ú–{Á‰»Ší•aŠw‰ï‘‰ï
‚RKoike Y et al. Changes in Hepatic Functional Reserve after
Percutaneous Tumor Ablation for Hepatocellular Carcinoma@2003@•Ä‘Á‰»Ší•aŠw‰ï
‚SKoike
Y et al. Risk factors for recurring hepatocellular carcinoma differ according
to infected hepatitis virus-an analysis of 236 consecutive patients with a
single lesion. Hepatology 2000 Dec;32(6):1216-23
‚TShiratori
Y,et al. Interferon therapy after tumor ablation improves prognosis in patients
with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med
2003 Feb 18;138(4):299-306